Follow Us On :
About Us
Company Profile
From the Chairman's Desk
Vision, Core Values
Milestones
Board of Directors
Management Profile
Mergers & Acquisitions
International Operations
Strategy
Subsidiaries
Bell, Sons & Co. (Druggists) Ltd.
Nova Pharmaceuticals Australasia Pty Ltd.
Relonchem Limited
Time Cap Labs, Inc.
R & D Capabilities
Quality Policy
Corporate Social Responsibility
World Wide Operations
Formulation Business
Overview
Markets
USA
Europe
South East Asia
Africa
Russia & CIS
Latin America
Australasia
Manufacturing Facilities
Locations (Goa/ Southport - UK)
R & D
CRAMS
Out Licensing
Business Development
Investor Relations
Financial Results
Annual Reports
Quarterly Reports
Analysts Presentation
Compliances
Shareholding Pattern
PD
Contact Us
News
Press Release
Media Gallery
Industry Overview
Health and Illness
Oncology And Critical Care
The Disorders Of The Mind And Nerves
Neurological Disorder
Mental Disorders
Skin Infections And Ulcers
Gastro - Intestinal Disorders (GI)
Cough Remedies
Women's Health
Bacterial Infections And Its Treatment
Careers
Overview
Values
Life at Marksans
Contact Us
Investor Relations
Financial Results
Annual Reports
Quarterly Reports
Analysts Presentation
Compliances
Shareholding Pattern
PD
Contact Us
Home
Investor Relations
Financial Results
Quarterly Reports
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
September 2005
December 2005
March 2006
June 2006
September 2006
December 2006
March 2007
June 2007
September 2007
December 2007
June 2008
June 2009
September 2009
December 2009
March 2010
March 2011
June 2011
September 2011
March 2012
June 2012
September 2012
December 2012
March 2013
June 2013
September 2013
Standalone Results
Consolidate Results
December 2013
Standalone Results
Consolidate Results
Review Report 2014
December 2014
June 2014
September 2014
March 2015
June 2015
September 2015
December 2015
March 2016
June 2016
September 2016
December 2016
March 2017
© Copyright 2013 Marksans Pharma.
